Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.

Slides:



Advertisements
Similar presentations
MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.
Advertisements

V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?
The future perspectives in transrectal prostate ultrasound guided biopsy Sung Il Hwang, Hak Jong Lee Prostate International Volume 2, Issue 4, Pages
Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with.
The PSA Era is not Over for Prostate Cancer
Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.
Volume 71, Issue 6, Pages (June 2017)
Volume 69, Issue 3, Pages (March 2016)
Volume 72, Issue 2, Pages (August 2017)
Contemporary Clinical Trials
Volume 4, Issue 5, Pages (September 2017)
Volume 56, Issue 6, Pages (December 2009)
Prostate Cancer: Highlights from 2006
Volume 63, Issue 1, Pages (January 2013)
Volume 53, Issue 5, Pages (May 2008)
European Urology Oncology
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Volume 65, Issue 6, Pages (June 2014)
Volume 66, Issue 1, Pages (July 2014)
Volume 69, Issue 3, Pages (March 2016)
European Urology Oncology
Towards Early and More Specific Diagnosis of Prostate Cancer
Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 199, Issue 4, Pages e768-e769 (April 2018)
Volume 62, Issue 6, Pages (December 2012)
Volume 67, Issue 4, Pages (April 2015)
Volume 73, Issue 4, Pages (April 2018)
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions  Anwar R. Padhani, Jeffrey Weinreb, Andrew.
Volume 73, Issue 2, Pages (February 2018)
The PSA Era is not Over for Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 68, Issue 4, Pages (October 2015)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Volume 65, Issue 4, Pages (April 2014)
Volume 68, Issue 6, Pages (December 2015)
Volume 66, Issue 3, Pages (September 2014)
Volume 65, Issue 1, Pages (January 2014)
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Optimising Hormone Therapy in Advanced Disease
European Urology Oncology
European Urology Oncology
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study  Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
European Urology Oncology
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 73, Issue 1, Pages (January 2018)
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
European Urology Oncology
Volume 65, Issue 3, Pages (March 2014)
Volume 75, Issue 4, Pages (April 2019)
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Volume 69, Issue 1, Pages (January 2016)
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
Oncoforum Urology: Prostate Cancer 2008 at a Glance
European Urology Oncology
Volume 51, Issue 5, Pages (May 2007)
Salvage Local Treatments After Focal Therapy for Prostate Cancer
European Urology Oncology
European Urology Oncology
European Urology Oncology
Introduction European Urology Supplements
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
European Urology Oncology
Presentation transcript:

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria Panebianco, Maria C. Valerio, Alessandro Giuliani, Martina Pecoraro, Isabella Ceravolo, Giovanni Barchetti, Carlo Catalano, Anwar R. Padhani  European Urology Oncology  Volume 1, Issue 3, Pages 208-214 (August 2018) DOI: 10.1016/j.euo.2018.03.008 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Patient flows and cost associated with diagnosis and therapy in the transrectal ultrasound-guided systematic biopsy (TRUS-Bx) pathway. pts=patients; PCa=prostate cancer; mpMRI=multiparametric magnetic resonance imaging; TRUS-SB=TRUS-guided saturation biopsy; TRUS-TB=TRUS-guided targeted biopsy; csPCa=clinically significant PCa; ciPCa=clinically insignificant PCa; RP=radical prostatectomy; RT=radiotherapy; FT=focal therapy; AS=active surveillance. * If all RT was image-guided radiation therapy. European Urology Oncology 2018 1, 208-214DOI: (10.1016/j.euo.2018.03.008) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Patient flows and costs associated with diagnosis and therapy in the multiparametric magnetic resonance imaging–guided targeted biopsy (mpMRI-Bx) pathway. pts=patients; TRUS-Bx=transrectal ultrasound-guided systematic biopsy; PCa=prostate cancer; TRUS-SB=TRUS-guided saturation biopsy; TRUS-TBx= TRUS-guided targeted biopsy; csPCa=clinically significant PCa; ciPCa=clinically insignificant PCa; RP=radical prostatectomy; RT=radiotherapy; FT=focal therapy; AS=active surveillance. * If all RT was image-guided radiation therapy. European Urology Oncology 2018 1, 208-214DOI: (10.1016/j.euo.2018.03.008) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Survival functions for the TRUS/Bx and the mp-MRI/Bx strategies depicting time to reach definitive diagnosis. European Urology Oncology 2018 1, 208-214DOI: (10.1016/j.euo.2018.03.008) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 208-214DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 208-214DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.